<DOC>
	<DOCNO>NCT02494687</DOCNO>
	<brief_summary>Gastroparesis digestive disorder motility stomach either slow absent . The gastroparesis prevent normal digestion occur . The purpose study provide oral Domperidone offer U.S. Food Drug Administration ( FDA ) expand access program , patient , base treat doctor 's assessment , could benefit , prokinetic effect relief refractory gastroesophageal reflux disease upper gastrointestinal ( GI ) symptom , gastroparesis , chronic constipation .</brief_summary>
	<brief_title>Domperidone Expanded Access Program Oncology Patients With Gastroparesis Who Have Failed Standard Therapy</brief_title>
	<detailed_description>At discretion Investigator , 10-30 mg oral domperidone administer QID ( four time day ) . The Investigator start patient 10 mg four time day 2 week , increase 20 mg four time day 2 week . The participant evaluate time point . If participant still relief symptom investigator may increase dose 30mg four time day .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Gastroparesis</mesh_term>
	<mesh_term>Domperidone</mesh_term>
	<criteria>1 . Male female 2 . Age 18 old 3 . Symptoms manifestation secondary GERD ( e.g. , persistent esophagitis , heartburn , upper airway sign symptom respiratory symptom ) , gastrointestinal motility disorder nausea , vomit , severe dyspepsia severe chronic constipation refractory standard therapy . 4 . Patients must comprehensive evaluation ( physical exam also may include EGD , gastric empty study , clinically necessary ) eliminate cause symptom . 5 . Patient sign informed consent administration domperidone inform patient potential adverse event include : increase prolactin level extrapyramidal sideeffects breast change cardiac arrhythmia include QT prolongation death History , current , arrhythmias include ventricular tachycardia , ventricular fibrillation Torsade des Pointes . Patients minor form ectopy ( PACs ) necessarily exclude . 1 . Clinically significant bradycardia , sinus node dysfunction , heart block . Prolonged QTc ( QTc &gt; 450 millisecond male , QTc &gt; 470 millisecond female ) . 2 . Clinically significant electrolyte disorder . 3 . Gastrointestinal hemorrhage obstruction 4 . Presence prolactinoma ( prolactinreleasing pituitary tumor ) . 5 . Pregnant breast feed female 6 . Known allergy domperidone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>